New drug vimseltinib aims to tame chronic GVHD in failed treatments
NCT ID NCT06619561
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD) who have not improved after at least two prior treatments. About 48 participants will take vimseltinib daily for up to two years. The goal is to see if the drug can control the disease and reduce symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vimseltinib (a drug taken by mouth)
- What this could lead to
- If successful, this could offer a new treatment option for people with chronic GVHD who have not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Orlando
RECRUITINGOrlando, Florida, 32804, United States
-
Avera Cancer Institute
RECRUITINGSioux Falls, South Dakota, 57105, United States
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Duke University Hospital
RECRUITINGDurham, North Carolina, 27705, United States
-
Emory University Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
-
Henry Ford Cancer Institute
RECRUITINGDetroit, Michigan, 48202, United States
-
Intermountain Health
RECRUITINGSalt Lake City, Utah, 84143, United States
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Oncology Hematology Care Clinical Trials, LLC
RECRUITINGCincinnati, Ohio, 45242, United States
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
-
Ronald Regan UCLA Medical Center
RECRUITINGLos Angeles, California, 90095, United States
-
St. David's South Austin Medical Center
RECRUITINGAustin, Texas, 78704, United States
-
The Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
Tristar Bone Marrow Transplant
RECRUITINGNashville, Tennessee, 37203, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University of California Irvine Health
RECRUITINGOrange, California, 92868-3201, United States
-
University of Illinois Medical Center - Hematology & Oncology
RECRUITINGChicago, Illinois, 60612, United States
-
University of Kansas Cancer Center-Westwood
RECRUITINGWestwood, Kansas, 66205, United States
-
University of Kentucky Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
-
Washington University School of Medicine - Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.